One Bite, Two Patients: Disparate Clinical Courses Following Simultaneous Crotalus oreganus abyssus Envenomation

Brick, 1982, Rattlesnake venom-induced myokymia, Muscle Nerve, 5, S98 LoVecchio, 2005, Myokymia after snake envenomation in Arizona, Wilderness Environ Med, 16, 116, 10.1580/1080-6032(2005)16[116:MASEIA]2.0.CO;2 French, 2004, Mojave toxin in venom of Crotalus helleri (southern Pacific rattlesnake): molecular and geographic characterization, Toxicon, 44, 781, 10.1016/j.toxicon.2004.08.008 Gutmann, 1991, AAEM minimonograph# 37: facial and limb myokymia, Muscle Nerve, 14, 1043, 10.1002/mus.880141102 Ranawaka, 2013, Neurotoxicity in snakebite—the limits of our knowledge, PLoS Negl Trop Dis, 7, e2302, 10.1371/journal.pntd.0002302 Cannon, 2008, Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune Fab antivenom, Ann Emerg Med, 51, 407, 10.1016/j.annemergmed.2007.09.036 Lavonas, 2011, Short-term outcomes after Fab antivenom therapy for severe crotaline snakebite, Ann Emerg Med, 57, 128, 10.1016/j.annemergmed.2010.06.550 Kleinschmidt, 2018, Acute adverse events associated with the administration of Crotalidae polyvalent immune fab antivenom within the North American Snakebite Registry, Clin Toxicol (Phila), 56, 1115, 10.1080/15563650.2018.1464175 Bush, 1999, Neurotoxicity associated with suspected southern Pacific rattlesnake (Crotalus viridis helleri) envenomation, Wilderness Environ Med, 10, 247, 10.1580/1080-6032(1999)010[0247:NAWSSP]2.3.CO;2 Harvey, 2001, Twenty years of dendrotoxins, Toxicon, 39, 15, 10.1016/S0041-0101(00)00162-8 Harris, 1989, Snake venoms in science and clinical medicine. 3. Neuropharmacological aspects of the activity of snake venoms, Trans R Soc Trop Med Hyg, 83, 745, 10.1016/0035-9203(89)90313-1 Brick, 1987, Timber rattlesnake venom-induced myokymia: evidence for peripheral nerve origin, Neurology, 37, 1545, 10.1212/WNL.37.9.1545 Ruha, 2017, The epidemiology, clinical course, and management of snakebites in the North American Snakebite Registry, J Med Toxicol, 13, 309, 10.1007/s13181-017-0633-5 Vohra, 2008, Fasciculations after rattlesnake envenomations: a retrospective statewide poison control system study, Clin Toxicol (Phila)., 46, 117, 10.1080/15563650701638925 Clark, 1997, Successful treatment of crotalid-induced neurotoxicity with a new polyspecific crotalid fab antivenom, Ann Emerg Med, 30, 54, 10.1016/S0196-0644(97)70111-2 Richardson, 2007, Rattlesnake envenomation with neurotoxicity refractory to treatment with crotaline fab antivenom, Clin Toxicol (Phila)., 45, 472, 10.1080/15563650701338187 Higuchi, 1999, Bradykinin-potentiating peptides and C-type natriuretic peptides from snake venom, Immunopharmacology, 44, 129, 10.1016/S0162-3109(99)00119-8 Dart, 2001, Efficacy, safety, and use of snake antivenoms in the United States, Ann Emerg Med, 37, 181, 10.1067/mem.2001.113372 Sabroe, 1997, Angiotensin–converting enzyme (ACE) inhibitors and angio-oedema, Br J Dermatol, 136, 153, 10.1111/j.1365-2133.1997.tb14887.x